Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

BACKGROUND: Many patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR had significantly superior efficacy over octreotide LAR. This analysis explores the effi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Endocr Disord
Autors principals: Bronstein, Marcello D., Fleseriu, Maria, Neggers, Sebastian, Colao, Annamaria, Sheppard, Michael, Gu, Feng, Shen, Chiung-Chyi, Gadelha, Mônica, Farrall, Andrew J., Hermosillo Reséndiz, Karina, Ruffin, Matthieu, Chen, YinMiao, Freda, Pamela
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818908/
https://ncbi.nlm.nih.gov/pubmed/27039081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-016-0096-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars